{"filing":{"accession_number":"0001193125-26-337197","cik":"0000718937","ticker":"STAA","company_name":"STAAR SURGICAL CO","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-05","primary_document":"staa-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/718937/000119312526337197/staa-20260805.htm"},"events":[{"id":25583,"run_id":23219,"accession_number":"0001193125-26-337197","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Warren Foust was appointed President, Chief Executive Officer, and Board member effective August 4, 2026, following an extensive global search. Deborah Andrews transitioned from Interim Co-CEO to Executive Vice President and Chief Financial Officer. The appointment includes substantial compensation arrangements including a base salary of $730,000 and significant equity grants.","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26459,"accession_number":"0001193125-26-337197","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Warren Foust was appointed President and Chief Executive Officer and new Board member effective August 4, 2026, following an extensive global search. While the disclosure also includes substantial compensation details (base salary of $730,000, equity grants totaling hundreds of thousands of shares/options, and severance arrangements), the principal disclosed action is Foust's appointment to the CEO role and Board. Deborah Andrews' transition from Interim Co-CEO to EVP and CFO is a secondary appointment. The appointment of a new CEO is material to investors as it represents a significant leadership change at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T00:04:49.260721+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26460,"accession_number":"0001193125-26-337197","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the Board's appointment of Warren Foust as President and CEO and a new Board member effective August 4, 2026, following an extensive global search. While Ms. Andrews' promotion to EVP is also mentioned, the principal disclosed action centers on Foust's appointment to the top executive role. This is a material executive leadership change affecting investor assessment of the company's strategic direction and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T00:04:49.260721+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26459,"accession_number":"0001193125-26-337197","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Warren Foust was appointed President and Chief Executive Officer and new Board member effective August 4, 2026, following an extensive global search. While the disclosure also includes substantial compensation details (base salary of $730,000, equity grants totaling hundreds of thousands of shares/options, and severance arrangements), the principal disclosed action is Foust's appointment to the CEO role and Board. Deborah Andrews' transition from Interim Co-CEO to EVP and CFO is a secondary appointment. The appointment of a new CEO is material to investors as it represents a significant leadership change at the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T00:04:49.260721+00:00","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-08-06"},{"id":26460,"accession_number":"0001193125-26-337197","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the Board's appointment of Warren Foust as President and CEO and a new Board member effective August 4, 2026, following an extensive global search. While Ms. Andrews' promotion to EVP is also mentioned, the principal disclosed action centers on Foust's appointment to the top executive role. This is a material executive leadership change affecting investor assessment of the company's strategic direction and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T00:04:49.260721+00:00","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-08-06"}]}